Login to Your Account



Walvax May Be China’s Largest Biotech Conglomerate with Genor Biopharma Buy

By Cornelia Zou
Contributing Writer

Wednesday, October 30, 2013

HONG KONG – With its latest acquisition, China’s Walvax Biotechnology Co. is raising the ante on its investments to $600 million, hoping to leverage its growing size into a profitable pipeline of, among other things, monoclonal antibodies (MAbs).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription